Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac526
Abstract: Abstract Efficient resource allocation is essential for effective pandemic response. We measured host biomarkers in 420 patients presenting with moderate coronavirus disease 2019 and found that different biomarkers predict distinct clinical outcomes. Interleukin (IL)–1ra, IL-6,… read more here.
Keywords: host biomarkers; coronavirus disease; disease; moderate coronavirus ... See more keywords
Short-term Pregnancy Outcomes After Nirmatrelvir–Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Sign Up to like & getrecommendations! Published in 2022 at "Obstetrics and Gynecology"
DOI: 10.1097/aog.0000000000004900
Abstract: Most pregnant patients who received nirmatrelvir–ritonavir treatment for mild-to-moderate coronavirus disease 2019 (COVID-19) tolerated treatment without adverse effects. This is a descriptive study of pregnant patients who received nirmatrelvir–ritonavir therapy from April 16, 2022, through… read more here.
Keywords: mild moderate; moderate coronavirus; nirmatrelvir ritonavir; ritonavir treatment ... See more keywords